Egalet Corp (EGLT) 10.60 $EGLT
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 10, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
LGCY: 13.35 (+0.51), AMKR: 8.90 (-0.02), EPRS: 7.67 (+0.67), MFLX: 14.99 (+0.16), MGPI: 14.00 (-0.39), GFN: 9.20 (+0.25), EGLT: 10.60 (+0.58), HRTX: 10.29 (+0.39), PFMT: 6.02 (-0.02), ACHN: 10.89 (-0.20), AGIO: 118.55 (+0.11), QLYS: 47.95 (+1.46), YDLE: 13.07 (+1.14), CBMG: 24.32 (-1.17)
Egalet (EGLT) Looks Good: Stock Moves 9.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 8:25AM CST
Egalet (EGLT) was a big mover last session, with shares rising over 9% on the day.
LCI: 57.78 (-0.91), EGLT: 10.60 (+0.58)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 11:44AM CST
CALX: 8.65 (-0.03), NES: 3.52 (+0.13), RVP: 5.14 (-0.42), RL: 135.20 (-0.60), SR: 1.25 (+0.08), MWA: 9.19 (+0.09), OHGI: 1.82 (-0.12), GENE: 8.04 (+1.90), CALI: 1.35 (+0.06), WPRT: 6.06 (+0.26), RSYS: 2.15 (+0.05), EGLT: 10.60 (+0.58), PACB: 6.96 (-0.06), ACHN: 10.89 (-0.20), BBSI: 39.78 (+0.84), AVEO: 0.84 (-0.06), CBLI: 3.24 (+0.05), ENG: 1.85 (-0.06), PLNR: 6.63 (-0.07)
NASDAQ, NYSE, and OTC-listed Companies Webcast Live to Investors: February 5 at VirtualInvestorConferences.com
PR Newswire - Mon Feb 02, 11:45AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
EGLT: 10.60 (+0.58), EVGN: 10.20 (+0.23), CPG.TO: 32.64 (+0.14), CPG: 26.20 (+0.16)
Egalet to Present at Upcoming Conferences in February
CNW Group - Mon Feb 02, 7:29AM CST
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
, a specialty pharmaceutical company focused on developing and commercializing effective pain medications while delivering peace of mind to physicians and patients, today announced that Bob Radie, president and chief executive officer, will present at upcoming conferences:
EGLT: 10.60 (+0.58)
Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market
Matt's Stocks - Seeking Alpha - Thu Jan 29, 7:06AM CST
The past year for Elite Pharmaceuticals ( OTCQB:ELTP ) has been quite remarkable. While the stock price has taken investors on a bit of a roller coaster ride, the company's business trajectory has been exceptional. In the past year, we have seen...
EGLT: 10.60 (+0.58), ACT: 285.37 (+3.71), PFE: 34.64 (-0.23), ACUR: 0.55 (+0.01)
Egalet (EGLT) Stock Gains Today on Price Target Increase
at The Street - Mon Jan 26, 8:53AM CST
Egalet (EGLT) shares are climbing after analysts at Canaccord Genuity raised its price target to $18 from $12 today.
EGLT: 10.60 (+0.58)
Nasdaq stocks posting largest volume increases
AP - Fri Jan 23, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
EGLE: 9.98 (-0.02), SIBC: 21.10 (+0.22), EGLT: 10.60 (+0.58), GLBZ: 12.65 (+0.35), NERV: 4.68 (+0.09), LPHI: 0.23 (unch), SAL: 28.70 (unch), TGLS: 9.89 (+0.09), EGRX: 20.98 (+1.45), WVFC: 11.02 (-0.45), NATL: 26.86 (-0.11), ATNY: 1.97 (+0.07)
Egalet up on HAL study
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 10:38AM CST
EGLT: 10.60 (+0.58), ZGNX: 1.43 (+0.05), ALKS: 71.40 (-1.89), ACUR: 0.55 (+0.01)
Strength Seen in Egalet (EGLT): Stock Soars 23.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 8:25AM CST
Egalet (EGLT) was a big mover last session, with its shares surging almost 24% on the day.
BCRX: 10.06 (-0.09), EGLT: 10.60 (+0.58)
Egalet Announces Positive Top-Line Results From Oral Human Abuse Liability Study of Abuse-Deterrent Morphine, Egalet-001
GlobeNewswire - Thu Jan 22, 7:10AM CST
Egalet Corporation (Nasdaq:EGLT) ("Egalet" today announced positive results from a Category 3 human abuse liability (HAL) study of Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. The clinical HAL study demonstrated that in nondependent, recreational opioid users, the abuse potential of manipulated Egalet-001 taken orally was significantly lower than that for manipulated MS Contin (morphine sulfate controlled-release).
EGLT: 10.60 (+0.58)
ORYZON Appoints Greg Weaver as Global Chief Financial Officer
PR Newswire Europe - Mon Jan 12, 2:01AM CST
CAMBRIDGE, Massachusetts and BARCELONA, Spain, January 12, 2015 /PRNewswire/ --
ATOS: 1.67 (+0.11), EGLT: 10.60 (+0.58)
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 10, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
LGCY: 13.35 (+0.51), AMKR: 8.90 (-0.02), EPRS: 7.67 (+0.67), MFLX: 14.99 (+0.16), MGPI: 14.00 (-0.39), GFN: 9.20 (+0.25), EGLT: 10.60 (+0.58), HRTX: 10.29 (+0.39), PFMT: 6.02 (-0.02), ACHN: 10.89 (-0.20), AGIO: 118.55 (+0.11), QLYS: 47.95 (+1.46), YDLE: 13.07 (+1.14), CBMG: 24.32 (-1.17)
Egalet (EGLT) Looks Good: Stock Moves 9.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 8:25AM CST
Egalet (EGLT) was a big mover last session, with shares rising over 9% on the day.
LCI: 57.78 (-0.91), EGLT: 10.60 (+0.58)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 11:44AM CST
CALX: 8.65 (-0.03), NES: 3.52 (+0.13), RVP: 5.14 (-0.42), RL: 135.20 (-0.60), SR: 1.25 (+0.08), MWA: 9.19 (+0.09), OHGI: 1.82 (-0.12), GENE: 8.04 (+1.90), CALI: 1.35 (+0.06), WPRT: 6.06 (+0.26), RSYS: 2.15 (+0.05), EGLT: 10.60 (+0.58), PACB: 6.96 (-0.06), ACHN: 10.89 (-0.20), BBSI: 39.78 (+0.84), AVEO: 0.84 (-0.06), CBLI: 3.24 (+0.05), ENG: 1.85 (-0.06), PLNR: 6.63 (-0.07)
NASDAQ, NYSE, and OTC-listed Companies Webcast Live to Investors: February 5 at VirtualInvestorConferences.com
PR Newswire - Mon Feb 02, 11:45AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
EGLT: 10.60 (+0.58), EVGN: 10.20 (+0.23), CPG.TO: 32.64 (+0.14), CPG: 26.20 (+0.16)
Egalet to Present at Upcoming Conferences in February
CNW Group - Mon Feb 02, 7:29AM CST
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
, a specialty pharmaceutical company focused on developing and commercializing effective pain medications while delivering peace of mind to physicians and patients, today announced that Bob Radie, president and chief executive officer, will present at upcoming conferences: EGLT: 10.60 (+0.58)
Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market
Matt's Stocks - Seeking Alpha - Thu Jan 29, 7:06AM CST
The past year for Elite Pharmaceuticals ( OTCQB:ELTP ) has been quite remarkable. While the stock price has taken investors on a bit of a roller coaster ride, the company's business trajectory has been exceptional. In the past year, we have seen...
EGLT: 10.60 (+0.58), ACT: 285.37 (+3.71), PFE: 34.64 (-0.23), ACUR: 0.55 (+0.01)
Egalet (EGLT) Stock Gains Today on Price Target Increase
at The Street - Mon Jan 26, 8:53AM CST
Egalet (EGLT) shares are climbing after analysts at Canaccord Genuity raised its price target to $18 from $12 today.
EGLT: 10.60 (+0.58)
Nasdaq stocks posting largest volume increases
AP - Fri Jan 23, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
EGLE: 9.98 (-0.02), SIBC: 21.10 (+0.22), EGLT: 10.60 (+0.58), GLBZ: 12.65 (+0.35), NERV: 4.68 (+0.09), LPHI: 0.23 (unch), SAL: 28.70 (unch), TGLS: 9.89 (+0.09), EGRX: 20.98 (+1.45), WVFC: 11.02 (-0.45), NATL: 26.86 (-0.11), ATNY: 1.97 (+0.07)
Egalet up on HAL study
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 10:38AM CST
EGLT: 10.60 (+0.58), ZGNX: 1.43 (+0.05), ALKS: 71.40 (-1.89), ACUR: 0.55 (+0.01)
Strength Seen in Egalet (EGLT): Stock Soars 23.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 8:25AM CST
Egalet (EGLT) was a big mover last session, with its shares surging almost 24% on the day.
BCRX: 10.06 (-0.09), EGLT: 10.60 (+0.58)
Egalet Announces Positive Top-Line Results From Oral Human Abuse Liability Study of Abuse-Deterrent Morphine, Egalet-001
GlobeNewswire - Thu Jan 22, 7:10AM CST
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced positive results from a Category 3 human abuse liability (HAL) study of Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. The clinical HAL study demonstrated that in nondependent, recreational opioid users, the abuse potential of manipulated Egalet-001 taken orally was significantly lower than that for manipulated MS Contin (morphine sulfate controlled-release). EGLT: 10.60 (+0.58)
ORYZON Appoints Greg Weaver as Global Chief Financial Officer
PR Newswire Europe - Mon Jan 12, 2:01AM CST
CAMBRIDGE, Massachusetts and BARCELONA, Spain, January 12, 2015 /PRNewswire/ --
ATOS: 1.67 (+0.11), EGLT: 10.60 (+0.58)
